





“ Calling the Parasite’s Bluff ”

Professor David Molyneux

Calling the Parasite's Bluff




Sir Ronald Ross



Addressing the Poverty Agenda: the MDGs




Eradicate
Extreme Poverty
and Hunger



Reduce
Child Mortality



Improve
Maternal Health



Combat
HIV/AIDS, Malaria
and other Diseases




A Global Partnership
for Development

Calling the Parasite's Bluff

Sleeping Sickness	Oncocerciasis Lymphatic Filariasis
Atoxyl Suramin Pentamidine	Ivermectin (Suramin) Doxycycline
Leishmaniasis	Malaria
Stilbamidine	Proguanil LAPDAP

Calling the Parasite's Bluff



Blindness

Direct cost of medical care
Appropriate/Inappropriate
Medical poverty trap
Permanent poverty
as no earned income

Complete dependence
on community
Reduced longevity
Burden on carers
and loss of carer income

Disablement
Deformity and stigma
Reduced social/
Marital prospects

Disablement

Reduced Performance
In education

Educational Disruption -
Children become carers

Reduced/no ability to access/
afford education

Deformity

Reduced Performance
In education

Educational Disruption -
Children become carers

Reduced/no ability to access/
afford education

Stigma



The role of Pharma in NTDs



Merck & Co Inc

“Mectizan for as long as needed” for onchocerciasis and filariasis in Africa



GlaxoSmithKline

Albendazole for lymphatic filariasis at least to 2020



Pfizer

Azithromycin for trachoma 120 million doses



Johnson & Johnson

Mebendazole for intestinal worms



Sanofi Aventis

Support for drugs for sleeping sickness treatment



Eisai

Provision of DEC for filariasis



Merck Serono

Donation of 250 m tablets annually of praziquantel (100 m treatments)



Gilead

Ambisome for visceral leishmaniasis



Novartis

Continuing commitment to MDT for leprosy; triclabendazole for fascioliasis

Roadmap for implementation & the London declaration

 ACCELERATING WORK
TO OVERCOME THE GLOBAL IMPACT OF
NEGLECTED TROPICAL DISEASES
A ROADMAP FOR IMPLEMENTATION




- The Director-General launched the NTD roadmap during the historic London meeting – Uniting to combat neglected tropical diseases: ending the neglect and reaching 2020 goals – featuring Bill Gates, Margaret Chan and 9 pharmaceutical company CEOs on 30 January 2012
- The roadmap inspires unprecedented support to overcome NTDs
- The London Declaration was endorsed during the meeting



Calling the Parasite's Bluff



IVCC is a Product Development Partnership investing donor funds in R&D to overcome barriers to innovation in vector control



A-WOL Industry Collaborations



Global Alliance for the Elimination of Lymphatic Filariasis



- **Political stability, ensuring country commitment**
- **Limited expertise and human capacity-communities to central government**
- **Environmental degradation, climate change, natural disaster frequency**
- **Migration, population and urbanisation**
- **Water resources, rainfall uncertainties**
- **Need for cross sector interaction**
- **New pandemic threats override chronic endemic problems**

- **Partnerships take time to mature**
- **Reach a comfort zone-parity of esteem for all partners**
- **Resources/incentives necessary for cross talk between partnerships**
- **Partnerships essential but complex, time consuming and resource intensive**
- **LSTM has the historic experience, endemic country links, donor support and a track record of successful delivery**

LSTM

LIVERPOOL SCHOOL
OF TROPICAL MEDICINE

